BioSpace News Archive

Launching with hearty Series A rounds, these new companies are ready to run.

After four people in the Pfizer-BioNTech’s and three people in Moderna’s COVID-19 vaccine trials developed temporary facial weakness or paralysis, some people became concerned that it could happen to them. But experts suggest that the condition, known as Bell’s palsy, is fairly prevalent in the population and generally transient.

FDA Granted Breakthrough Therapy Designation for Sotorasib Sotorasib Application Being Reviewed Under FDA Real-Time Oncology Review (RTOR) Pilot Program

MARGENZA (margetuximab-cmkb) is the first HER2-targeted therapy to have improved progression-free survival (PFS) versus Herceptin® ( trastuzumab), both combined with chemotherapy, in a head-to-head Phase 3 clinical trial MARGENZA is approved, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens

The Honourable Catherine McKenna, Minister of Infrastructure and Communities and the Honourable Mona Fortier, Minister of Middle Class Prosperity and Associate Minister of Finance, on behalf of the Honourable Patty Hajdu, Minister of Health, and Dr.

Administration of neflamapimod during the subacute phase after transient ischemia induced stroke in rats promoted functional recovery Associated increased levels of brain-derived neurotrophic factor (BDNF) suggest the effects were mediated by increasing synaptic plasticity

Briotech, Inc. announced a distribution agreement with Intermodeco 2004 SRL, for the country of Romania . Intermodeco will begin distribution of imported Briotech Pure Hypochlorous (HOCl)

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 2,250,000 shares of its common stock at a price to the public of $42.00 per share. All of the shares to be sold in the offering are being sold by Phathom. The gross proceeds to Phathom from the

Certara, Inc. (“Certara”), a global leader in biosimulation by 2019 revenue, today announced that on December 15, 2020, it closed its upsized initial public offering of 33,413,250 shares of common stock at $23.00 per share. The closing includes 4,358,250 shares sold upon full exercise of the underwriters’ option to purchase additional shares of common stock. Certara sold 14,630,000 shares of its common stock, and certain

Advanced Bifurcation Systems, Inc., a Livermore, CA-based maker of the ABS System, a proprietary stent delivery system that is specifically designed to efficiently treat coronary bifurcation lesions, is pleased to announce the first closing of an $11 million Series A equity financing.